Small-cap biotech led the sector: XBI rose 2.5% and BBC 4.3% against NBI +0.9%, while XLV slipped 0.6%. Pre-open single-name catalysts cut both ways, with Merck KGaA's $20-per-ADS cash bid for Silence and Disc Medicine's roughly 38% jump on Phase 3 APOLLO set against EyePoint's 80%-plus collapse on LUCIA.

AI and chip stocks recouped part of last week's rout, with the Philadelphia semiconductor index snapping an eight-session losing streak, lifting the Nasdaq 100 1.2% and the S&P 500 0.4% while the Dow slipped 0.1% and most stocks outside tech fell. Weekend unrest in France knocked European indexes down more than 1% and pushed bond yields up worldwide.

Merck KGaA agreed to buy Silence Therapeutics for $20 per ADS in cash, about $1.3B in equity value, through a UK scheme of arrangement expected to close in Q1 2027; lead siRNA divesiran heads into Phase 3 in polycythemia vera.

Why it matters: Merck KGaA is paying an 82% premium to Silence's 30-day average of $10.99, roughly $1.1B in enterprise value once cash is netted, and the price came out of a competitive sale process. The asset is divesiran, a TMPRSS6 siRNA that produced an 88% response rate versus 19% on placebo in the Phase 2 SANRECO study. Phase 3 will dose every 12 weeks, and that interval is the commercial case against Takeda and Protagonist's Mimrylo, approved in August as a weekly self-injection. It is Kai Beckmann's second big swing as CEO after June's $11B-plus Bio-Techne agreement. Merck now carries Phase 3 cost and timing, plus zerlasiran and SLN312, both unpartnered after Hansoh and AstraZeneca handed rights back.

Source: Endpoints

More: Fierce Biotech; BioSpace

Roche licensed ex-Greater China rights to a slate of Hansoh ADCs for $400M upfront, another $110M on the first anniversary and up to $15B in milestones plus tiered royalties.

Why it matters: Hansoh takes each ADC through Phase 1, covering two in-house preclinical programs plus targets Roche nominated, before Roche runs global development outside Greater China; Hansoh keeps an option to co-fund two programs for extra commercial upside. That is $510M of committed cash by the first anniversary for an undisclosed, preclinical portfolio. It is Roche's second trip to Hansoh after last year's $80M upfront for CDH17 ADC HS-20110, and Hansoh already supplies GSK with B7-H3 ADC ris-rez. The deal landed three days after MOFCOM's draft rules barred foreign acquisitions of some Chinese platforms while carving out licensing, so the structure fits Beijing's new lines.

Source: Endpoints

More: Fierce Biotech; BioSpace

Bitopertin met both co-primary endpoints and every key secondary in the pivotal Phase 3 APOLLO trial in erythropoietic protoporphyria, setting up a year-end resubmission after February's complete response letter.

Why it matters: APOLLO answers the question February's CRL asked. In 183 patients with EPP or XLP, 60mg bitopertin cut metal-free PPIX 41.4% versus placebo over six months (p<0.0001) and added 12.2 hours a month of pain-free time in light (p=0.0010), the clinical-outcome link the FDA said the accelerated filing lacked. Phototoxic reaction rates fell (p<0.0001); dizziness hit half of treated patients, mostly mild and transient, with nothing above grade 3. Disc will refile by year-end for a mid-2027 decision, against Scenesse, the only marketed therapy, and dersimelagon, which could be approved next year. Shares rose about 38% Monday, and Disc launched a $350M stock and pre-funded warrant offering that evening.

Source: Endpoints

More: Fierce Biotech; BioPharma Dive

AbbVie's ABBV-466, Skyrizi plus the α4β7 antibody trosunilimab, reached 30.2% endoscopic remission at week 12 versus 21.3% for Skyrizi alone in a 300-patient Phase 2 Crohn's study; a roughly 2,000-patient follow-on trial began in July. — Endpoints

Gilead's oral α4β7 inhibitor emvistegrast posted 31% clinical remission at 200mg versus 8% on placebo at week 12 in the 238-patient Phase 2 SWIFT ulcerative colitis study at UEG Week, a cross-trial read above Entyvio; Phase 3 starts in 2027. — Endpoints

EyePoint is cutting 53% of staff and ending its wet AMD trials early after Duravyu's second Phase 3, LUCIA (n=475), missed non-inferiority to Eylea by 3.7 letters of visual acuity at week 52; DME pivotal trials COMO and CAPRI read out in Q4 2027, and shares lost more than 80% Monday. — Fierce Pharma

GSK won accelerated FDA approval for Jemperli in stage 2-3 locally advanced dMMR/MSI-H rectal cancer, the first immunotherapy for the setting, on AZUR-1's 47% 12-month clinical complete response rate by central review (n=116); full data come at ESMO and confirmatory AZUR-2 reads out in 2028. — Fierce Pharma

Veradermics' oral minoxidil VDPHL01 met both primary endpoints in the 536-patient Phase 3 '304' trial in male pattern hair loss, adding 28.6 (once daily) and 36.4 (twice daily) hairs/cm² at month 6 versus 6.6 on placebo (p<0.0001). — Endpoints

Viatris won FDA approval for Ryzumvi (phentolamine ophthalmic solution 0.75%, partnered with Opus Genetics) in presbyopia, a label expansion announced Sunday. — Endpoints

Sanofi broke ground on a Germany insulin API plant with government-backed support. — BioSpace

Roche paused future investments in Germany, the latest drugmaker to pull back there. — Fierce Pharma

Merck KGaA / Silence Therapeutics — acquisition at $20 per ADS in cash, ~$1.3B equity value (~$1.1B EV), 82% premium to the 30-day average, UK scheme of arrangement, close Q1 2027 (see The Big 3). — Endpoints

Roche / Hansoh — ex-Greater China ADC licence, $400M upfront plus $110M at one year, up to $15B in milestones, tiered royalties (see The Big 3). — Endpoints

Lilly / Metis TechBio — collaboration on Metis' AiLNP ionizable-lipid discovery platform, upfront in the low double-digit millions, up to $1.1B in total plus royalties. — Fierce Biotech

Ambrose Healthcare / AM-Pharma — acquisition for up to EUR161M (~$181M) in upfront and HPP commercial milestones, split undisclosed; ilofotase alfa (alkaline phosphatase ERT) for hypophosphatasia; Pfizer paid $87.5M for an option in 2015 and walked. — Fierce Biotech

Sanofi / ScionxBio — screening pact for ScionxBio's long-acting mRNA candidates, terms undisclosed; ScionxBio's first deal since splitting from Eleven Therapeutics. — Endpoints

No notable private financings since yesterday.

TriGemX Bio (ex-Kallyope) — going public via SPAC merger with TCGX Acquisition Corp. at ~$600M post-transaction equity value, with a $160M PIPE (TCGX, Viking Global, ADAR1) and ~$246M expected cash; Nasdaq: TGEM; elismetrep (TRPM8 blocker) in Phase 3 for acute migraine, first readout mid-2027. — Fierce Biotech

Disc Medicine (IRON) — launched a proposed $350M offering of common stock and pre-funded warrants Monday evening after APOLLO; unpriced at send (see The Big 3). — StreetInsider

Illicit peptide markets are drawing broader public-health scrutiny, a JAMA reply noted — relevant mainly as a signal of tightening oversight around gray-market compounding and direct-to-consumer peptide demand rather than as a core biotech catalyst. — JAMA